Free tool
FAERS Monitor: Opcon-A
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 020065 or its brand name (Opcon-A, Naphazoline Hydrochloride, Pheniramine Maleate). Reports on generic versions are filed under their own applications.
Reports
1,660
Serious
86
5% of reports
Hospitalization
25
Death reported
8
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- mydriasis446
- eye irritation425
- vision blurred214
- drug ineffective206
- eye pain158
- ocular hyperaemia149
- instillation site pain104
- condition aggravated74
- eye pruritus66
- lacrimation increased60
- eye swelling48
- visual impairment47
- product quality issue41
- headache39
- burning sensation38
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 1 |
| 2005 | 2 |
| 2006 | 2 |
| 2007 | 1 |
| 2008 | 114 |
| 2009 | 137 |
| 2010 | 126 |
| 2011 | 148 |
| 2012 | 126 |
| 2013 | 105 |
| 2014 | 88 |
| 2015 | 70 |
| 2016 | 128 |
| 2017 | 132 |
| 2018 | 25 |
| 2019 | 74 |
| 2020 | 44 |
| 2021 | 18 |
| 2022 | 50 |
| 2023 | 75 |
| 2024 | 49 |
| 2025 | 72 |
| 2026 | 73 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,499 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| instillation site painSignal | 104 | 555.1 | 458.9 | 54,589 |
| mydriasisSignal | 446 | 456.2 | 420.6 | 195,230 |
| eye irritationSignal | 425 | 94.2 | 86.8 | 38,933 |
| ocular hyperaemiaSignal | 149 | 39.9 | 34.2 | 5,607 |
| eye painSignal | 158 | 35.6 | 30.7 | 5,275 |
| lacrimation increasedSignal | 60 | 25.2 | 19.7 | 1,370 |
| eye pruritusSignal | 66 | 24.9 | 19.7 | 1,492 |
| vision blurredSignal | 214 | 19.8 | 17.4 | 3,815 |
| eye swellingSignal | 48 | 16.4 | 12.4 | 678 |
| burning sensationSignal | 38 | 6.9 | 5.0 | 185 |
| visual impairmentSignal | 47 | 4.8 | 3.6 | 139 |
| product quality issueSignal | 41 | 3.8 | 2.8 | 83 |
| condition aggravatedSignal | 74 | 3.1 | 2.5 | 104 |
| drug ineffective | 206 | 2.0 | 1.7 | 106 |
| headache | 39 | 0.8 | 0.6 | 2 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.